Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Katherine Matthay

17PUBLICATIONS
66CO-AUTHORS
Gene and molecular therapyInfant and child healthRadiation therapyCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

Sort by Publication Date:
|May 12, 2026
Clinical and Biological Features of Response in Resistant Neuroblastoma to <sup>131</sup>I-Metaiodobenzylguanidine Radiotherapy in the Anti-GD2 Immunotherapy Era.

|Dec 23, 2025
Adaptive Clinical Neuroblastoma Risk Groups-Tailoring Treatment in Low- and Middle-Income Countries: An International Neuroblastoma Risk Group Project.

Wendy B London, Gabriela Villanueva, Derek Shyr

|Jun 23, 2025
Phase I Study of <sup>131</sup>I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial.

Thomas Cash, Araz Marachelian, Steven G DuBois

|Jun 01, 2024
Long-term follow-up of patients with intermediate-risk neuroblastoma treated with response- and biology-based therapy: A report from the Children's Oncology Group study ANBL0531.

Erin K Barr, Arlene Naranjo, Clare J Twist

|May 01, 2024
Late cognitive and adaptive outcomes of patients with neuroblastoma-associated opsoclonus-myoclonus-ataxia-syndrome: A report from the Children's Oncology Group.

Prerna Kumar, Victoria W Willard, Leanne Embry

|Oct 27, 2023
Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to <sup>131</sup> I-MIBG in patients with relapsed/refractory neuroblastoma.

Vandana Batra, Ajami Gikandi, Bruce Pawel

Pageof 3

Frequent Collaborators

7 joint publications

Steven G DuBois

4 joint publications

Susan L Cohn

4 joint publications

Julie R Park

4 joint publications

Barry Shulkin

4 joint publications

John M Maris

4 joint publications

Wendy B London

4 joint publications

Kieuhoa T Vo

3 joint publications

Brian Weiss

3 joint publications

Steve E Braunstein

2 joint publications

Judith G Villablanca

Frequent Collaborators

7 joint publications

Steven G DuBois

4 joint publications

Susan L Cohn

4 joint publications

Julie R Park

4 joint publications

Barry Shulkin